These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 8858462

  • 21. Disposition and safety of omapatrilat in subjects with renal impairment.
    Sica DA, Liao W, Gehr TW, Khan S, Jemal M, Delaney CL, Ferreira IM, Malhotra BK.
    Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407
    [Abstract] [Full Text] [Related]

  • 22. Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit.
    Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G.
    Br J Clin Pharmacol; 2009 Aug; 68(2):174-80. PubMed ID: 19694735
    [Abstract] [Full Text] [Related]

  • 23. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
    Yoon EJ, Lee WI, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG.
    Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
    [Abstract] [Full Text] [Related]

  • 24. Cefsulodin pharmacokinetics in patients with various degrees of renal function.
    Matzke GR, Keane WF.
    Antimicrob Agents Chemother; 1983 Mar; 23(3):369-73. PubMed ID: 6847169
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.
    Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E.
    Clin Nephrol; 1993 Jan; 39(1):53-8. PubMed ID: 8428409
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE, Opsahl JA, Abraham PA, Schwenk MH, Andreadis NA, Antal EJ, Matzke GR.
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [Abstract] [Full Text] [Related]

  • 29. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S, Tan K, Layton G, Leclerc V, Weil A.
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [Abstract] [Full Text] [Related]

  • 30. Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
    Saengsuwan P, Jaruratanasirikul S, Jullangkoon M, Aeinlang N.
    J Med Assoc Thai; 2010 Jul; 93(7):784-8. PubMed ID: 20649056
    [Abstract] [Full Text] [Related]

  • 31. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
    St Peter JV, Borin MT, Hughes GS, Kelloway JS, Shapiro BE, Halstenson CE.
    Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA, Kohli RK, Harrison NJ, Schentag JJ.
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects.
    Danielson B, Querin S, LaRochelle P, Sultan E, Mouren M, Bryce T, Stepniewski JP, Lenfant B.
    J Cardiovasc Pharmacol; 1994 Sep; 23 Suppl 4():S50-9. PubMed ID: 7527102
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
    Szałek E, Tomczak H, Kamińska A, Grabowski T, Smuszkiewicz P, Matysiak K, Wolc A, Kaczmarek Z, Grześkowiak E.
    Adv Med Sci; 2012 Sep; 57(2):217-23. PubMed ID: 22968336
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.
    Halstenson CE, Guay DR, Opsahl JA, Hirata CA, Olanoff LS, Novak E, Ko H, Cathcart KS, Matzke GR.
    Antimicrob Agents Chemother; 1990 Apr; 34(4):519-23. PubMed ID: 2344159
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.